Results 21 to 30 of about 56,599 (248)

Effect of etanercept on post-traumatic proliferative vitreoretinopathy [PDF]

International Journal of Ophthalmology, 2019
AIM: To evaluate the safety and efficacy of intravitreal etanercept in the inhibiting of proliferative vitreoretinopathy (PVR) in a model of penetrating ocular injury.
Xiao-Feng Chen, Mei Du, Xiao-Hong Wang, Hua Yan   +3 more
doaj   +1 more source

Maternal and Fetal-Placental Effects of Etanercept Treatment During Rats’ Pregnancy

Frontiers in Physiology, 2022
Etanercept is a tumor necrosis factor alpha (TNF-α) inhibitor chronically used to treat autoimmune diseases. However, the use of etanercept during pregnancy still needs to be further investigated.
Gabriel Gomes Araujo, Rinaldo Rodrigues dos Passos Junior, Rosaline Rocha Lunardi, Gustavo Tadeu Volpato, Thaigra Sousa Soares, Fernanda Regina Giachini, Fernanda Regina Giachini, Victor Vitorino Lima   +7 more
doaj   +1 more source

Etanercept biosimilars [PDF]

Rheumatology International, 2014
Etanercept was the first tumour necrosis factor alpha antagonist approved in the USA for the treatment of rheumatoid arthritis, in 1998, and then for other diseases. With the etanercept patent set to expire in the EU in 2015, a number of etanercept copies have reached the production phase and are undergoing clinical trials, with the promise of being ...
Azevedo, Valderilio F., Galli, Nathalia, Kleinfelder, Alais, D’Ippolito, Julia, Urbano, Paulo C. M.   +4 more
openaire   +2 more sources

Etanercept attenuates myocardial ischemia/reperfusion injury by decreasing inflammation and oxidative stress. [PDF]

PLoS ONE, 2014
The protective role of etanercept in myocardial ischemia/reperfusion is not well understood. The aim of this study was to investigate whether etanercept modulates neutrophil accumulation, TNF-α induction and oxidative stress in an ischemia/reperfusion ...
Mei Yang, Jianchang Chen, Jing Zhao, Mei Meng   +3 more
doaj   +1 more source

Targeting anti-inflammatory treatment can ameliorate injury-induced neuropathic pain. [PDF]

PLoS ONE, 2013
Tumor necrosis factor-α plays important roles in immune system development, immune response regulation, and T-cell-mediated tissue injury. The present study assessed the net value of anti-tumor necrosis factor-α treatment in terms of functional recovery ...
Katsuyuki Iwatsuki, Tetsuya Arai, Hideyuki Ota, Shuichi Kato, Tadahiro Natsume, Shigeru Kurimoto, Michiro Yamamoto, Hitoshi Hirata   +7 more
doaj   +1 more source

Long-term safety and effectiveness of etanercept in JIA: an 18-year experience from the BiKeR registry

Arthritis Research & Therapy, 2020
Background At present, etanercept represents the most commonly prescribed biologic agent for juvenile idiopathic arthritis (JIA) treatment. Children and adolescents with JIA are often treated with etanercept over long periods, sometimes even into ...
Giulia Armaroli, Ariane Klein, Gerd Ganser, Michael J. Ruehlmann, Frank Dressler, Anton Hospach, Kirsten Minden, Ralf Trauzeddel, Ivan Foeldvari, Jasmin Kuemmerle-Deschner, Frank Weller-Heinemann, Andreas Urban, Gerd Horneff   +12 more
doaj   +1 more source

Comparison of the inhibitory effect of tocilizumab and etanercept on the progression of joint erosion in rheumatoid arthritis treatment

Scientific Reports, 2022
We compared the efficacy of tocilizumab and etanercept in inhibiting radiographic progression of joint destruction in rheumatoid arthritis. Overall, 187 patients treated with etanercept or tocilizumab were selected.
Shinya Hayashi, Tsukasa Matsubara, Toshihisa Maeda, Koji Fukuda, Keiko Funahashi, Marowa Hashimoto, Ken Tsumiyama, Tomoyuki Kamenaga, Yoshinori Takashima, Tomoyuki Matsumoto, Shotaro Tachibana, Ryosuke Kuroda   +11 more
doaj   +1 more source

Baseline characteristics and patient reported outcome data of patients prescribed etanercept: web-based and telephone evaluation [PDF]

, 2011
<p>Background: The anti-TNF inhibitor, etanercept is administered as a once or twice weekly subcutaneous injection for the treatment of rheumatoid arthritis, psoriasis, ankylosing spondylitis, psoriatic arthritis and juvenile idiopathic arthritis ...
Alex McConnachie, Susan Maycock, Pumford, N., McConnachie, A., Neil Pumford, Gordon M Crawford, Wade, A.G., Volker Koscielny, Koscielny, V., Alan G Wade, Crawford, G.M., Maycock, S.   +11 more
core   +1 more source

Etanercept alleviates psoriasis by reducing the Th17/Treg ratio and promoting M2 polarization of macrophages

Immunity, Inflammation and Disease, 2022
Introduction This study aimed to investigate the effect of etanercept in psoriasis and its underlying mechanism. Methods Female mice were treated with imiquimod (IMQ) to induce psoriasis, and intraperitoneally administered etanercept (0.1–0.4 mg/ml). The
Xiaoqing Li, Ming Jiang, Xia Chen, Weiguo Sun   +3 more
doaj   +1 more source

Intra-articular vs. systemic administration of etanercept in antigen-induced arthritis in the temporomandibular point. Part I: histological effects

Pediatric Rheumatology Online Journal, 2009
Background Temporomandibular joint (TMJ) arthritis in children causes alterations in craniomandibular growth. This abnormal growth may be prevented by an early anti-inflammatory intervention.
Nyengaard Jens R, Pedersen Thomas K, Küseler Annelise, Stoustrup Peter, Kristensen Kasper D, Hauge Ellen, Herlin Troels   +6 more
doaj   +1 more source